These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25962087)

  • 1. Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.
    van Schie KA; Wolbink GJ; Rispens T
    MAbs; 2015; 7(4):662-71. PubMed ID: 25962087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype.
    Tatarewicz SM; Juan G; Swanson SJ; Moxness MS
    J Immunol Methods; 2012 Aug; 382(1-2):93-100. PubMed ID: 22609464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody.
    Araujo J; Zocher M; Wallace K; Peng K; Fischer SK
    J Pharm Biomed Anal; 2011 Jul; 55(5):1041-9. PubMed ID: 21466939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new cross-reactive idiotype-defined family in the phthalate humoral immune response of mice. I. Linkage of VH-Xmp to IgCH allotype locus and mapping with respect to other known VH genes.
    Luo SC; Bankert RB
    J Immunol; 1987 Apr; 138(7):2311-5. PubMed ID: 3104458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunogenicity of biopharmaceuticals: Which consequences during the treatment of rheumatoid arthritis?].
    Goupille P
    Rev Med Interne; 2016 May; 37(5):343-9. PubMed ID: 26526777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the NIDS® rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics.
    Pan J; Small T; Qin D; Li S; Wang L; Chen D; Pauley C; Verch T; Kaplanski C; Bakhtiar R; Vallejo YR; Yin R
    J Pharmacol Toxicol Methods; 2011; 63(2):150-9. PubMed ID: 20868758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics.
    Xue L; Rup B
    AAPS J; 2013 Jul; 15(3):893-6. PubMed ID: 23761225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The internal image of IgG in cross-reactive anti-idiotypic antibodies against human rheumatoid factors.
    Fong S; Gilbertson TA; Carson DA
    J Immunol; 1983 Aug; 131(2):719-24. PubMed ID: 6863929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural similarities in the kappa light chains of human rheumatoid factor paraproteins and serum immunoglobulins bearing a cross-reactive idiotype.
    Fong S; Chen PP; Gilbertson TA; Fox RI; Vaughan JH; Carson DA
    J Immunol; 1985 Sep; 135(3):1955-60. PubMed ID: 3926892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.
    Bloem K; van Leeuwen A; Verbeek G; Nurmohamed MT; Wolbink GJ; van der Kleij D; Rispens T
    J Immunol Methods; 2015 Mar; 418():29-38. PubMed ID: 25637408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatoid arthritis patients have elevated antibodies to cross-reactive and non cross-reactive antigens from Proteus microbes.
    Rashid T; Jayakumar KS; Binder A; Ellis S; Cunningham P; Ebringer A
    Clin Exp Rheumatol; 2007; 25(2):259-67. PubMed ID: 17543151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-existing Antibody: Biotherapeutic Modality-Based Review.
    Gorovits B; Clements-Egan A; Birchler M; Liang M; Myler H; Peng K; Purushothama S; Rajadhyaksha M; Salazar-Fontana L; Sung C; Xue L
    AAPS J; 2016 Mar; 18(2):311-20. PubMed ID: 26821802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.
    Xue L; Clements-Egan A; Amaravadi L; Birchler M; Gorovits B; Liang M; Myler H; Purushothama S; Manning MS; Sung C
    AAPS J; 2017 Nov; 19(6):1576-1586. PubMed ID: 29110222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients.
    van Schouwenburg PA; Bartelds GM; Hart MH; Aarden L; Wolbink GJ; Wouters D
    J Immunol Methods; 2010 Oct; 362(1-2):82-8. PubMed ID: 20833178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The majority of human monoclonal IgM rheumatoid factors express a "primary structure-dependent" cross-reactive idiotype.
    Chen PP; Goñi F; Fong S; Jirik F; Vaughan JH; Frangione B; Carson DA
    J Immunol; 1985 May; 134(5):3281-5. PubMed ID: 3920316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection.
    Bendtzen K
    Front Immunol; 2015; 6():109. PubMed ID: 25904911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.